Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS: This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enrolled 226 adults having major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria, active suicidal ideation with intent, and need for psychiatric hospitalization. Patients were randomized 1:1 to esketamine 84 mg or placebo nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care treatment (initial psychiatric hospitalization and newly initiated or optimized oral antidepressant[s] therapy). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score (primary endpoint) was analyzed using analysis of covariance (ANCOVA), and change in Clinical Global Impression of Severity of Suicidality Revised version (CGI-SS-r; key secondary endpoint) score was analyzed using ANCOVA on ranks with treatment difference estimated using the Hodges-Lehmann estimate. RESULTS: Greater improvement in MADRS total score was observed with esketamine + standard-of-care versus placebo + standard-of-care at 24 hours (least-squares mean difference [SE]: -3.8 [1.39]; 95% CI, -6.56 to -1.09; 2-sided P = .006), as well as at earlier (4 hours) and later time points during 4-week double-blind treatment. The difference between groups in the severity of suicidality was not statistically significant (median of treatment difference [95% CI]: 0.0 [-1.00 to 0.00]; 2-sided P = .107). The most common adverse events among esketamine-treated patients were dizziness, dissociation, headache, nausea, and somnolence. CONCLUSIONS: These findings demonstrate rapid and robust efficacy of esketamine nasal spray in reducing depressive symptoms in severely ill patients with major depressive disorder who have active suicidal ideation with intent. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03039192.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredIn the citing paper
“Most recently, Fu and colleagues demonstrated moderately significant AD effects with adjunct intranasal (IN) esketamine but failed to demonstrate an effect for suicidality, the trial’s other primary outcome.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
In the citing paper
“In 2019, esketamine nasal spray (marketed as Spravato) was approved as an adjunctive AD treatment for TRD in the United States and the European Union, becoming the first novel-acting antidepressant approved in decades [104,105].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Kessler, R. C. (2005) · JAMA · doi:10.1001/jama.293.20.2487 · Cited by 1,073
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationThe European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390
Deisenhammer, E. A., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03904 · Cited by 315
Holma, K. M., Melartin, T. K., Haukka, J., Holma, I. A. K., Sokero, T. P., & Isometsä, E. T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09050627 · Cited by 248
Deisenhammer, E., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · PubMed · Cited by 237
Lifetime suicide risk in major depression: sex and age determinants
Blair-West, G. W., Cantor, C. H., Mellsop, G. W., & Eyeson-Annan, M. L. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00004-x · Cited by 233
Suicide Attempts Among Patients Starting Depression Treatment With Medications or Psychotherapy
Simon, G. E., & Savarino, J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1029 · Cited by 168
Cited by
Items 301–375 of 375
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0123
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0150
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0124
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0139
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.126
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.111
Index by Use: Commonly Prescribed For (bold for FDA approved)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.155
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.121
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0131
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.114
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.141
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0105
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0153
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.118
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0112
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0129
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.116
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0103
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0135
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0109
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.151
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0149
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.104
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0120
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0142
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0125
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0154
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.136
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.137
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0138
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0107
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.102
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.127
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.140
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0108
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.117
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.133
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0122
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0134
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0148
Schnell wirksame Antidepressiva
Şen, Z. D., Danyeli, L. V., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_10
Moussiopoulou, J., Slapakova, L., Kirsch, B., Mei, E. W. Y., & Schüle, C. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100110
O USO DE ANTIDEPRESSIVOS E O RISCO AUMENTADO DE SUICÍDIO/AUTOCÍDIO: uma revisão de literatura
Coutinho, M. A. P., Coelho, T. C., & Silva, C. D. L. E. (2023) · Psicologia e Saúde em Debate · doi:10.22289/2446-922x.v9n1a21
Skoblenick, K. J., Hsu, M., & Swainson, J. (2023) · Journal of Patient Experience · doi:10.1177/23743735231218866
Janski, A. M., Hristidis, V. C., Zorumski, C. F., & Conway, C. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00064-6
The Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
PRINCIPAIS E INOVADORAS MEDIDAS FARMACOLÓGICAS PARA O TRATAMENTO DO TRANSTORNO DEPRESSIVO MAIOR
Cardoso, J. M. G., Marinho, K. K., Pereira, I. A. B., da Costa, E. S. S., Vitória, B. T. D., Lino, A. T. D. S., Oliveira, B. N., Ribeiro, M. E. S., Pereira, G. M., da Vitória, B. T., et al. (2024) · Revista Contemporânea · doi:10.56083/rcv4n4-127
Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009464772.048
Stahl, S. M., & Strawn, J. R. (2024) · doi:10.1017/9781009267526.026
REVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW
Kaushal, Y., GOYAL, P., & Sehgal, A. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024v17i8.51360
Kopeček, M., Andrashko, V., Knytl, P., & Horáček, J. (2024) · Psychiatrie pro praxi · doi:10.36290/psy.2024.024
Jha, M. K., Teeple, A., Shepherd, J., Gillespie, A., Grant, N., Mortimer, A., Kirkman, S., Middleton‐Dalby, C., & Joshi, K. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2463975
“Esketamine, an enantiopure formulation of S -ketamine, has shown efficacy in major trials 10,11 .”
Türkmen, C., Boesjes, R., Zandbergen, A.-F., Kamphuis, J., Viechtbauer, W., Schoevers, R. A., & van Dalfsen, J. H. (2025) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.25.1271 · Cited by 1
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Self-citationKetamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Intranasal Esketamine: The Baby in the Bathwater
Price, M. Z., & Price, R. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250168
Rozjabek, H., Li, N., Hartmann, H., Fu, D. J., Canuso, C. M., & Jamieson, C. (2022) · Figshare · doi:10.6084/m9.figshare.20290994
Self-citationFu, D.-J., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · Figshare · doi:10.6084/m9.figshare.23935866
Self-citationAkutbehandlung schwerer depressiver Zustandsbilder
Tieden, S., & Kornacher, J. (2025) · Nervenheilkunde · doi:10.1055/a-2625-5639
“In einer Übersichtsarbeit wurde vor allem die therapeutische Beziehung zwischen Patienten Merke Die engmaschige Begleitung suizidaler Patienten durch den Bei fehlender Absprachefähigkeit ist . die Verlegung in ein geschütztes Setting erforderlich .”
Cutting, T., & Hartman, R. E. (2026) · Medicine Advances · doi:10.1002/med4.70051
Menon, T., Lu, A., Arulmozhi, A., Dri, C. E., Wong, S., Teopiz, K. M., Le, G. H., Lee, S. M. L., Weissman, C. R., & McIntyre, R. S. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117036 · Cited by 1
Yu, X., Shen, T., Zhang, T., Bao, R., Guo, Z., Feng, Z., Tong, L., Zhang, X., Ran, M., Sun, G., et al. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70641
Ding, X., Hashimoto, K., & Yang, J.-J. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111727
Benster, L. L., Kohn, J. N., Wade, B., Stapper, N., Weissman, C. R., Miron, J., Daskalakis, Z. J., & Appelbaum, L. G. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122107 · Cited by 2
Bhatt, K. V., Austin, T. A., Alam, D., Compton, J. N., Ellerman-Tayag, E., Awodele, G., Boerth, J. M., Periviliotis, D., Bismark, A. W., Singh, M. A., et al. (2026) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20260041
“However, this ease of use comes at a considerable healthcare cost, primarily due to the cost differences between the generic racemic formulation versus the patented IN esketamine formulation (13).”
Lv, Y., Yang, Z., Li, L., Xu, Y., Qin, Y., Deng, B., & ZHAI, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179153 · Cited by 1
Wu, Q., Li, W., Luo, Z., Wang, C., Lan, X., Shen, J., Chen, Z. X., Pan, J., Liu, X., Zhu, H., et al. (2026) · BMC Psychiatry · doi:10.21203/rs.3.rs-10020524/v1
Chen, L., Chen, Y., Zhao, Y., Feng, T., Song, X., Xie, F., Shen, J., He, J., Guo, J., & Zhong, L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1781915
Xie, J., Dong, J., Liao, H., Liu, S., He, Z., & Zeng, C. (2026) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000890
Pinzi, M., Cuomo, A., Rescalli, M. B., Pierini, C., & Fagiolini, A. M. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2714839
“The strongest randomized evidence in adults with MDD and acute suicidal ideation or behavior comes from the phase III ASPIRE I and ASPIRE II trials [24,25].”
InfluentialTreatments for individuals with suicidal thoughts: Use, indications, and helpfulness
Ballard, E. D., Hafermann, H. F., Hurst, K. T., Farmer, C., Greenstein, D. K., Kvarta, M. D., May, A. M., & Zarate, C. A. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101165
Borkowska, M., Witaszczyk, M., Sołtan, A., Wiktorzak, N., Lipska, J., Prządka, J., Kochan-Olszewska, D., Rudnicki, L., Pawlicki, J., Laskus, J., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6636
“(3,6,7) This early assessment window is clinically important because patients with active suicidal ideation may require immediate clinical stabilization while longer-term treatment strategies are initiated.”
InfluentialSOP: Vorgehen bei therapieresistenter Depression
Bschor, T., & Ochs, B. (2026) · PSYCH up2date · doi:10.1055/a-2842-5623
Kinney, M. M., & Bowers, Z. L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1949261
Metadata
- Authors
- Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M.
- Affiliations
- Janssen Research & Development (United States) (US)
- Yale University (US)
- Corresponding author
- Fu, Dong-Jing
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2020-05-12
- Volume
- 81
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3025905746
- Cited by
- 376
- References
- 13
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 32 · 2023: 50 · 2022: 34 · 2021: 30 · 2020: 166
- FWCI
- 41.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, nasal spray, major depressive disorder, suicidal ideation, rapid-acting antidepressants, psychiatric hospitalization, antidepressant-resistant depression, depressive symptom reduction, adverse events
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Young Adult, Suicidal Ideation, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.